

10th October, 2019 – For immediate release

Medcan Australia’s Cannabis Research Area construction complete and ODC inspection booked

Medcan Australia is pleased to announce the construction of its Cannabis Research Area is complete and the ODC (Office of Drug Control) have formally booked their inspection for 29th October 2019.

The completion of the Medcan Australia Cannabis Research Area is a significant milestone as, once the ODC have performed their inspection, it allows the cultivation and production, testing, stability trials and genetic profiling of Medcan Australia’s genetics and/or products.

Successful inspection of the Medcan Australia Cannabis Research Area by the ODC will allow:

- i) the issue of permits relating to Medcan Australia’s cultivation and production schedule
- ii) the implementation of Medcan Australia’s plant breeding and research programs
- iii) the ability to commence validation and stability trials of API’s and subsequent products
- iv) the ability to fast track and refine manufacture processes and protocols under Medcan Australia’s Manufacture Licence
- v) the advancement and improvement of cultivation, harvesting, trimming, drying and destruction processes



The completion of the Cannabis Research Area and subsequent ODC inspection, added to the recently announced successful import and export permits secured by Medcan Australia and one of their strategic supply partners for the first “Medcan Australia” branded products in to the Australian market, further advances Medcan Australia’s position as a leader in the Australian Medicinal Cannabis space.

Comments from Craig Cochran - CEO Medcan Australia:

Medcan Australia Founder, Craig Cochran said: "It has been a long hard road to reach this milestone. Australian Legislation, whilst implemented to ensure the high level of Australian Medicinal Cannabis companies, is a long and tedious path to navigate.

Craig Continued: "The Medcan Australia Cannabis Research Area is constructed using GMP standard finishes and implements extremely high-level cultivation and production practices. We are excited to host the ODC for their inspection and show case what we believe is a standard of cultivation and production that has not been seen anywhere in Australia to date.

Background

Medcan Australia was founded in 2016 and was one of the first Australian companies to be licensed by the Office of Drug Control (ODC) to cultivate and produce Medicinal Cannabis, manufacture Medicinal Cannabis products and import and export Medicinal Cannabis products. The company was founded with a single vision to provide Australian patients with high quality, fair priced Medicinal Cannabis products.

Medcan Australia are one of only a few companies in Australia to hold the full suite of ODC (Office of Drug Control) Licences, State Licences & DAWR Permit being:

- 1) Cultivation and Production Licence - no. MC013/17
- 2) Manufacture Licence - no. ML015/18
- 3) Research Licence – no. RL18/19
- 4) Import Licence - no. 1821087
- 5) Export Licence - no. 1821088
- 6) DAWR Permit - no. 0002005875
- 7) QLD Health Poison's Licence - no. AG007354718
- 8) QLD Wholesaling Approval – no. C-MC-1289

Medcan Australia will be producing a range of high quality Medicinal Cannabis strains with varying CBD & THC profiles to suit varying medicinal applications, with all of our products manufactured under GMP certification, ensuring consistent medicine for patients.

For Further Information please contact:



Gareth Ball
+61414860512
Po Box 4579, Springfield, QLD, Australia, 4300
gareth@medcanaustralia.com.au
www.medcanaustralia.com.au